Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400856 | 1.00 | SLC17A5 (0.54) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL29374576 | 1.00 | SLC17A5 (0.54) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL25320019 | 1.00 | SLC17A5 (0.54) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL30665728 | 0.91 | MDM4 (0.51) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL29202254 | 0.90 | TLR2 (0.50) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL5311930 | 0.87 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29401557 | 0.87 | SLC17A5 (0.43) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL5311923 | 0.87 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL27699497 | 0.87 | SLC17A5 (0.43) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL29398108 | 0.87 | SLC17A5 (0.58) | SLC17A5MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113788877-B | Novel insect kinin analogues and application thereof in aphid control | 中国农业大学 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022111713-A9 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| CN-114573686-A | Polypeptide containing disulfide bond and having serine protease activity inhibition function and application thereof | 中国医学科学院药物研究所 | 2022-06-03 | — | — | CN | disclosed |
| CN-113788877-A | Novel insect kinin analogs and application thereof in aphid control | 中国农业大学 | 2021-12-14 | — | — | CN | disclosed |
| US-8969289-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110305663-A1 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-15 | — | — | US | disclosed |
| US-6310040-B1 | FOR PROMOTING THE SURVIVAL OF PHOTORECEPTORS IN A MAMMAL | CEPHALON, INC. | 2001-10-30 | — | — | US | disclosed |
| US-5776897-A | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5703045-A | NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5652214-A | ENHANCING SURVIVAL OF NEURONAL CELLS IN HEAD AND SPINAL CORD AFTER INJURY, ALSO TREATMENT OF AGING, ALZHEIMER*S, STROKE, EPILEPSY | CEPHALON, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0604605-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0670729-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305663-A1 | SERUM ALBUMIN BINDING MOLECULES | FN1, ALB, FABP3 | SLC17A5 417/4885MDM4 3498/4885TP53 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.